Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Calo

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
CNS & Neurological Disorders Drug Targets|September 18, 2013
Synaptic dysfunction in synucleinopathiesOleg Anichtchik, Laura Calo, Maria Grazia Spillantini
Movement Disorders : Official Journal of the Movement Disorder Society|January 22, 2016
Synaptic failure and α-synucleinLaura Calo, Michal Wegrzynowicz, Jessica Santivañez-Perez, et al.
Nature Biotechnology|December 19, 2017
Labeling and identifying cell-specific proteomes in the mouse brainToke P Krogager, Russell J Ernst, Thomas S Elliott, et al.
Acta Neuropathologica|June 6, 2019
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease modelMichal Wegrzynowicz, Dana Bar-On, Laura Calo', et al.
Acta Neuropathologica|December 3, 2013
The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neuronsMariangela Iovino, Ulrich Pfisterer, Janice L Holton, et al.
Chembiochem : a European Journal of Chemical Biology|July 28, 2018
Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal CellsDaniel R Whiten, Yukun Zuo, Laura Calo, et al.
Neurobiology of Disease|August 25, 2019
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivoDarren J Schofield, Lorraine Irving, Laura Calo, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
CNS & Neurological Disorders Drug Targets|September 18, 2013
Synaptic dysfunction in synucleinopathiesOleg Anichtchik, Laura Calo, Maria Grazia Spillantini
Movement Disorders : Official Journal of the Movement Disorder Society|January 22, 2016
Synaptic failure and α-synucleinLaura Calo, Michal Wegrzynowicz, Jessica Santivañez-Perez, et al.
Nature Biotechnology|December 19, 2017
Labeling and identifying cell-specific proteomes in the mouse brainToke P Krogager, Russell J Ernst, Thomas S Elliott, et al.
Acta Neuropathologica|June 6, 2019
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease modelMichal Wegrzynowicz, Dana Bar-On, Laura Calo', et al.
Acta Neuropathologica|December 3, 2013
The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neuronsMariangela Iovino, Ulrich Pfisterer, Janice L Holton, et al.
Chembiochem : a European Journal of Chemical Biology|July 28, 2018
Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal CellsDaniel R Whiten, Yukun Zuo, Laura Calo, et al.
Neurobiology of Disease|August 25, 2019
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivoDarren J Schofield, Lorraine Irving, Laura Calo, et al.
Pageof 1